10月19日,维迪西妥单抗联合特瑞普利单抗(DV+T)对比化疗一线治疗HER2表达局部晚期或转移性尿路上皮癌(Ia/mUC)的III期RC48-C016研究在ESMO大会的主席论坛环节重磅亮相,并同步全文在线发表于顶级期刊《新英格兰医学杂志》,充分显示出国际学术界对这项研究的关注以及其突破性临床价值的认可。早在今年5月,荣昌生物就公告宣布RC48-C016研究达到PFS和OS的双终点,并于2025...
Source Link10月19日,维迪西妥单抗联合特瑞普利单抗(DV+T)对比化疗一线治疗HER2表达局部晚期或转移性尿路上皮癌(Ia/mUC)的III期RC48-C016研究在ESMO大会的主席论坛环节重磅亮相,并同步全文在线发表于顶级期刊《新英格兰医学杂志》,充分显示出国际学术界对这项研究的关注以及其突破性临床价值的认可。早在今年5月,荣昌生物就公告宣布RC48-C016研究达到PFS和OS的双终点,并于2025...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.